anastrozole


Also found in: Dictionary, Wikipedia.
Related to anastrozole: tamoxifen

anastrozole

 [ah-nas´trah-zōl″]
an aromatase inhibitor used for treatment of advanced breast carcinoma in postmenopausal women; it inhibits conversion of circulating androgens into estrogens.

anastrozole

Arimidex

Pharmacologic class: Nonsteroidal aromatase inhibitor

Therapeutic class: Antineoplastic

Pregnancy risk category D

Action

Reduces serum estradiol levels with no significant effect on adrenocorticoid or aldosterone level; decreases stimulating effect of estrogen on tumor growth

Availability

Tablets: 1 mg

Indications and dosages

Postmenopausal women with hormone receptor-unknown or hormone receptor-positive advanced breast cancer or with advanced breast cancer after tamoxifen therapy; adjuvant treatment for hormone receptor-positive breast cancer

Adults: 1 mg P.O. daily

Contraindications

• Hypersensitivity to drug or its components

• Women of childbearing age

Precautions

Use cautiously in:

• ischemic heart disease

• breastfeeding patients

• children (safety and efficacy not established).

Administration

• Verify that patient isn't pregnant before giving drug.

Adverse reactions

CNS: headache, weakness, dizziness, depression, paresthesia, lethargy

CV: chest pain, peripheral edema, vasodilation, hypertension, thromboembolic disease

EENT: pharyngitis

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, anorexia, dry mouth

GU: vaginal bleeding, leukorrhea, vaginal dryness, pelvic pain

Musculoskeletal: decreased bone mineral density, fractures, bone or back pain, muscle weakness

Respiratory: dyspnea, cough

Skin: rash

Other: food distaste, weight gain, swelling, hot flashes, flulike symptoms, tumor flare hypersensitivity reactions (including anaphylaxis, angioedema, urticaria)

Interactions

Drug-diagnostic tests. Hepatic enzymes, low-density lipoproteins, total cholesterol: increased levels

Patient monitoring

Monitor patient closely for hypersensitivity reactions.

• Check regularly for signs and symptoms of thromboembolic disease, especially dyspnea and chest pain.

• Monitor for circulatory overload (suggested by peripheral edema, cough, and dyspnea).

• Assess for signs and symptoms of depression. Evaluate patient for suicidal ideation.

• Monitor liver function test results.

Patient teaching

Instruct patient to immediately notify prescriber if signs and symptoms of hypersensitivity occur (such as itching or swelling of face, lips, or throat).

Advise patient to immediately report signs and symptoms of thromboembolic disease and circulatory overload.

• Emphasize importance of preventing pregnancy during therapy.

• Tell patient to contact prescriber if she develops signs or symptoms of depression.

• Caution patient to avoid driving and other hazardous activities until she knows how drug affects concentration and alertness.

• Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.

• Inform patient that she'll undergo regular blood testing during therapy.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

anastrozole

An aromatase inhibitor, which converts androstenedione to estradiol in peripheral fat.
 
Indications
Postmenopausal women with advanced oestrogen-dependent breast cancer that does not respond to tamoxifen; unlike tamoxifen, anastrozole is not associated with increased risk of endometrial cancer.

anastrozole

An anti-oestrogen drug. Anastrozole is an aromatase-inhibitor anti-estrogen drug used in the treatment of advanced breast cancer in post-menopausal women. An aromatase is an enzyme that promotes the conversion of testosterone to the aromatic compound oestradiol (estradiol). This process occurs in women, and its inhibition can reduce oestrogen levels which can be helpful in the control of oestrogen-dependent tumours. The side effects may include any of those due to oestrogen deficiency. A brand name is Arimidex.
References in periodicals archive ?
Group B was given anastrozole in the dose parallel to normal human dose and group C was given a dose 10 times higher than the normal dose for six months.
Since previous studies demonstrated that focal adhesion proteins are more likely regulated in uterine epithelia to change cell behavior (Kaneko et al., 2009), and that super-ovulatory drugs can alter expression of key molecules in the uterine epithelial cells during implantation (Hosie et al., 2003), anastrozole may act on focal adhesion proteins during implantation.
Treatment with aromatase inhibitors (anastrozole) is among the options (1,2,3,7,8,9).
Investigators of two large randomized trials of anastrozole versus clomiphene reported that clomiphene was superior to anastrozole for induction of ovulation in the first cycle of treatment.
Travis Tygart, the head of the United States Anti-Doping Agency, clarified that there is can be no ambiguity on the usage of either Anastrozole or Clomephine which are both prohibited at any time.
"Anastrozole is one of a class of medications called aromatase inhibitors, and these drugs stop the body from producing estrogen.
et al., "A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer," Breast Cancer Research and Treatment, vol.
13 ( ANI ): A new study has shown that taking the breast cancer drug anastrozole for five years reduces the chances of developing the disease in high risk post-menopausal women by 53 percent compared with women who took a placebo.
The aromatase inhibitor anastrozole (Arimidex) is not recommended by either ASCO or the USPSTF, with data awaited from the ongoing phase III, placebo-controlled British IBIS II (Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer) study.
"Cancer Research UK's crucial work in the laboratory is behind many important drugs, such as tamoxifen and herceptin, and our trials of drugs called aromatase inhibitors paved the way for the development of anastrozole - all of this is helping to give women with breast cancer more treatment options."
The scientists concluded that, "The combination of anastrozole and fulvestrant was superior to anastrozole alone or sequential anastrozole and fulvestrant for the treatment of HR-positive metastatic breast cancer, despite the use of a dose of fulvestrant that was below the current standard."
Half of the men received the aromatase inhibitor anastrozole in addition, which created estradiol deficiency.